Mai Capital Management Bristol Myers Squibb CO Transaction History

Mai Capital Management

$9.87 Billion
Q2 2024

A detailed history of Mai Capital Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mai Capital Management holds 142,940 shares of BMY stock, worth $7.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

142,940

Previous 609,267 76.54%

Holding current value

$7.6 Million

Previous $33 Million 82.03%

% of portfolio

0.06%

Previous 0.36%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$40.25 - $52.99 $18.8 Million - $24.7 Million	-466,327 Reduced 76.54%	142,940 $5.94 Million
Q1 2024 May 08, 2024	BUY	$47.98 - $54.4 $1.81 Million - $2.05 Million	37,626 Added 6.58%	609,267 $33 Million
Q4 2023 Feb 09, 2024	BUY	$48.48 - $57.85 $2.46 Million - $2.94 Million	50,796 Added 9.75%	571,641 $29.3 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $809,475 - $905,119	-13,983 Reduced 2.61%	520,845 $30.2 Million
Q2 2023 Aug 02, 2023	BUY	$63.71 - $70.74 $99,132 - $110,071	1,556 Added 0.29%	534,828 $34.2 Million
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $744,034 - $843,903	-11,323 Reduced 2.08%	533,272 $37 Million
Q4 2022 Feb 09, 2023	BUY	$68.48 - $81.09 $1.4 Million - $1.65 Million	20,373 Added 3.89%	544,595 $39.2 Million
Q3 2022 Nov 15, 2022	BUY	$0.13 - $76.84 $10,511 - $6.21 Million	80,861 Added 18.24%	524,222 $37.3 Million
Q2 2022 Jul 19, 2022	BUY	$72.62 - $79.98 $4.83 Million - $5.32 Million	66,461 Added 17.63%	443,361 $34.1 Million
Q1 2022 May 10, 2022	BUY	$61.48 - $73.72 $6.2 Million - $7.44 Million	100,915 Added 36.57%	376,900 $27.5 Million
Q4 2021 Feb 11, 2022	BUY	$53.63 - $62.52 $3.38 Million - $3.94 Million	62,972 Added 29.56%	275,985 $17.2 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $824,297 - $965,557	13,931 Added 7.0%	213,013 $12.6 Million
Q2 2021 Jul 19, 2021	BUY	$61.91 - $67.42 $407,429 - $443,691	6,581 Added 3.42%	199,082 $13.3 Million
Q1 2021 May 10, 2021	BUY	$59.34 - $66.74 $341,679 - $384,288	5,758 Added 3.08%	192,501 $12.2 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $9.29 Million - $10.5 Million	-160,922 Reduced 46.29%	186,743 $11.6 Million
Q3 2020 Oct 26, 2020	BUY	$57.43 - $63.64 $473,223 - $524,393	8,240 Added 2.43%	347,665 $21 Million
Q2 2020 Jul 27, 2020	BUY	$54.82 - $64.09 $10.4 Million - $12.1 Million	189,246 Added 126.01%	339,425 $20 Million
Q1 2020 Apr 16, 2020	BUY	$46.4 - $67.43 $2.79 Million - $4.06 Million	60,180 Added 66.87%	150,179 $8.37 Million
Q4 2019 Feb 03, 2020	BUY	$49.21 - $64.19 $1.35 Million - $1.77 Million	27,512 Added 44.03%	89,999 $5.78 Million
Q3 2019 Oct 29, 2019	SELL	$42.77 - $50.71 $783,589 - $929,057	-18,321 Reduced 22.67%	62,487 $3.17 Million
Q2 2019 Aug 15, 2019	SELL	$44.62 - $49.34 $2.62 Million - $2.89 Million	-58,650 Reduced 42.06%	80,808 $3.67 Million
Q1 2019 Apr 29, 2019	BUY	$45.12 - $53.8 $418,262 - $498,726	9,270 Added 7.12%	139,458 $6.65 Million
Q4 2018 Jan 30, 2019	BUY	$48.76 - $63.23 $256,916 - $333,158	5,269 Added 4.22%	130,188 $6.77 Million
Q3 2018 Oct 12, 2018	SELL	$55.19 - $62.25 $18,930 - $21,351	-343 Reduced 0.27%	124,919 $7.76 Million
Q2 2018 Aug 16, 2018	BUY	$50.53 - $62.98 $59,625 - $74,316	1,180 Added 0.95%	125,262 $6.93 Million
Q1 2018 Apr 17, 2018	BUY	$59.92 - $68.98 $53,928 - $62,082	900 Added 0.73%	124,082 $7.85 Million
Q4 2017 Jan 30, 2018	SELL	$59.94 - $65.35 $418,740 - $456,535	-6,986 Reduced 5.37%	123,182 $7.55 Million
Q3 2017 Oct 12, 2017	SELL	$55.23 - $63.74 $84,170 - $97,139	-1,524 Reduced 1.16%	130,168 $8.3 Million
Q2 2017 Aug 07, 2017	BUY	N/A	131,692	131,692 $7.34 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.

Account

Mai Capital Management Bristol Myers Squibb CO Transaction History